Q-omics provides the consensus-scored ME2P1 profile across patient tissues and cancer cell-line models. ME2P1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ME2P1 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, ME2P1 RNA expression shows 6,505 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, KIRC, and STAD as cancer lineages where ME2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ME2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ME2P1 survival associations across molecular data types. ME2P1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ME2P1 RNA expression–survival associations across cancer types. High ME2P1 expression shows unfavorable associations in TGCT, KIRC and LIHC, but favorable associations in SKCM, LUSC and COAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify SKCM as the clearest survival context for ME2P1 RNA expression.
This table summarizes ME2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ME2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ME2P1 shows higher tumor expression in KIRC, HNSC, COAD, PRAD and KIRP. The KIRC box plot shows higher ME2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.084, t-test p < 0.001).
This table shows molecular features associated with ME2P1 in patient tissues and cancer cell lines. In patient samples, ME2P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
